Advertisement

Agents and Actions

, Volume 21, Issue 1–2, pp 89–92 | Cite as

Short-term clinical trials of anti-rheumatoid drugs — an opinion

  • J. S. Dixon
Immunosuppression and Inflammation

Conclusion

Discussions pertaining to outcome and end-points in clinical trials in rheumatology have, in recent years, tended to disregard the so-called process measures in favour of measures of total health status, usually by questionnaires such as the Health Assessment Questionnaire (HAQ). This is perfectly reasonable in relation to the long-term benefits, or problems that might be expected of long-term therapy, but may not be sufficiently sensitive to detect the short-term differences between NSAID and ARD therapy. Until further properties of ARDs can be identified, or until a drug appears which is superior to present ARDs in terms of efficacy, then refined, cost-effective, short-term (about 20 weeks) trials using a small number of clinical and laboratory assessments in a small number of patients (15–30) represent an almost obligatory initial stage in the clinical development of new ARD therapy.

Keywords

Clinical Trial Health Status Clinical Development Process Measure Health Assessment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    D. L. Scott, P. T. Dawes, P. D. Fowler, et al.,Anti-rheumatic drugs and joint damage in rheumatoid arthritis. Q. J. Med. New Series54, No. 213, 49–59 (1985).Google Scholar
  2. [2]
    J. R. Kirwan, D. M. Chaput de Saintonge, C. R. B. Joyce and H. C. F. Currey,Clinical judgement in rheumatoid arthritis. III. British Rheumatologists' judgements of “change in response to therapy”. Ann. Rheum. Dis.43, 686–694 (1984).Google Scholar
  3. [3]
    J. S. Dixon, H. A. Bird, M. E. Pickup and V. Wright,A human model screening system for the detection of specific antirheumatic activity. Seminars in Arth. and Rheum.12, 185–190 (1982).Google Scholar
  4. [4]
    J. S. Dixon, H. A. Bird, M. F. R. Martin, F. McKenna and V. Wright,Biochemical and clinical changes occurring during the treatment of rheumatoid arthritis with novel anti-rheumatoid drugs. Int. J. Clin. Pharm. Res.5, 25–33 (1985).Google Scholar
  5. [5]
    J. S. Dixon,Biochemical Screening Systems for the Detection of Anti-rheumatic Activity. In:New Antiinflammatory Drugs: Mechanisms and Clinical Use. (Eds. A. Lewis and D. Furst) Publ. Marcel Dekker, Inc. New York 1987.Google Scholar
  6. [6]
    J. S. Dixon,Relationship between plasma viscosity or ESR and the Ritchie articular index. Br. J. Rheum.23, 233–235 (1984).Google Scholar

Copyright information

© Birkhäuser Verlag 1987

Authors and Affiliations

  • J. S. Dixon
    • 1
  1. 1.Clinical Pharmacology UnitRoyal Bath HospitalHarrogate

Personalised recommendations